Instrument Inactif

Communiqués Kane Biotech Inc Other OTC

Actions

CA4838091094

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

25/06	Kane Biotech signe un accord de licence avec I-MED Pharma	MT
25/06	Kane Biotech signe un accord de licence mondial avec I-MED Pharma Inc.	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.	25/06	AQ
Kane Biotech Announces First Quarter 2024 Financial Results	23/05	GL
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024	16/05	AQ
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map	15/05	GL
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map	15/05	AQ
Kane Biotech to Host Investor Webinar	16/04	GL
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products	15/04	GL
Canadian Investment Regulatory Organization Trade Resumption - KNE	11/04	AQ
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health	11/04	GL
Canadian Investment Regulatory Organization Trading Halt - KNE	11/04	AQ
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results	26/03	GL
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	20/03	GL
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow	19/03	GL
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow	19/03	AQ
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award	08/03	GL
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair	22/02	GL
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair	22/02	AQ
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray	31/01	GL
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray	31/01	AQ
Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium	25/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Kane Biotech Inc Other OTC

Actions

CA4838091094

Communiqués

Filtres